卵巢肿瘤患者血清CA_(125)的检测及其意义

Detection of serum CA_(125) in patients with ovarian tumors

目的:探讨CA125检测在卵巢肿瘤患者中的临床意义。方法:应用免疫放射分析法(IRMA)测定75例恶性卵巢肿瘤(包括上皮性恶性卵巢肿瘤62例,非上皮性恶性卵巢肿瘤13例)、19例子宫内膜异位症1、3例盆腔结缔组织炎、96例良性上皮性卵巢肿瘤、13例交界性卵巢肿瘤及52例健康女性的血清CA125值,并结合其临床表现作统计学分析。结果:恶性上皮性卵巢肿瘤患者血清CA125值明显高于良性卵巢肿瘤、交界性卵巢肿瘤和非上皮性恶性卵巢肿瘤患者,差异有显著性(P<0.01);但与子宫内膜异位症、盆腔结缔组织炎患者血清CA125值比较差异无显著性(P>0.05);血清CA125的表达与上皮性恶性卵巢肿瘤的临床分期、化疗疗效密切相关(P<0.01)。结论:血清CA125作为卵巢肿瘤标记物的重要指标,应在其诊断及治疗中常规检测。

Objective： To investigate the change of serum CA125 level and its clinical significance in patients with ovarian tumors. Methods： Serum CA125 level was determined by immunoradiometry in 75 patients with malignant ovarian tumors, 96 benign ovarian tumors, 13 borderline ovarian tumors. 19 endometriosis, 13 pelvic inflammation, and 52 healthy women. Results： Serum CA125 content in patients with epithelial ovarian cancers was significantly higher than those with non-epithelial ovarian cancers, benign ovarian tumors, and borderline ovarian tumors （P〈0.01）, but it was not superior to that in patients with endometriosis and pelvic inflammation （P〉0. 05）. CA125 level was correlated with clinical staging and chemotherapeutic efficacy in epithelial ovarian cancers （P〈0. 01）, Conclusion.. Serum CA125 maybe a marker for ovarian cancer.